A report from the European Hyperoxaluria Consortium (OxalEurope) Registry on a large cohort of patients with primary hyperoxaluria type 3.
chronic kidney disease
epidemiology
genetics
nephrocalcinosis
oxalate
primary hyperoxaluria type 3
urolithiasis
Journal
Kidney international
ISSN: 1523-1755
Titre abrégé: Kidney Int
Pays: United States
ID NLM: 0323470
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
25
09
2020
revised:
04
03
2021
accepted:
11
03
2021
pubmed:
19
4
2021
medline:
26
8
2021
entrez:
18
4
2021
Statut:
ppublish
Résumé
Outcome data in primary hyperoxaluria type 3 (PH3), described as a less severe form of the PH's with a low risk of chronic kidney disease, are scarce. To investigate this, we retrospectively analyzed the largest PH3 cohort reported so far. Of 95 patients, 74 were followed over a median of six years. Median age of first symptoms and diagnosis were 1.9 and 6.3 years, respectively. Urolithiasis was the major clinical feature observed in 70% of pediatric and 50% of adult patients. At most recent follow-up available for 56 of the 95 patients, 21.4% were in chronic kidney disease stages 2 or more. For better characterization, samples from 49 patients were analyzed in a single laboratory and compared to data from patients with PH1 and PH2 from the same center. Urinary oxalate excretion was not significantly different from PH1 and PH2 (median: 1.37, 1.40 and 1.16 mmol/1.73m
Identifiants
pubmed: 33865885
pii: S0085-2538(21)00386-0
doi: 10.1016/j.kint.2021.03.031
pii:
doi:
Substances chimiques
Oxalates
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
621-635Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.